Literature DB >> 6246268

Herpes simplex virus glycoproteins: isolation of mutants resistant to immune cytolysis.

N A Machtiger, B A Pancake, R Eberle, R J Courtney, S S Tevethia, P A Schaffer.   

Abstract

Immune cytolysis mediated by antibody and complement is directed against components of the major herpes simplex virus (HSV) glycoprotein complex (molecular weight, 115,000 to 130,000), comprised of gA, gB, and gC, and against glycoprotein gD-all present on the surfaces of infected cells. Tests with a temperature-sensitive (ts) mutant of HSV-1 (tsA1) defective in glycoprotein synthesis at the nonpermissive temperature (39 degrees C) demonstrated that over 90% of mutant-infected cells maintained at 39 degrees C and treated with antibody and complement were not lysed, presumably due to the absence of viral glycoproteins on the surface of infected cells at this temperature. Furthermore, a small number of tsA1-infected cells could be detected among a large excess of wild-type virus-infected cells by virtue of their failure to be lysed at 39 degrees C by antibody and complement. Making use of the involvement of viral glycoproteins in immune cytolysis and the ability of cells infected with glycoprotein-defective mutants to escape cytolysis, we sought mutants defective in the expression of individual viral glycoproteins. For this purpose, antisera directed against the VP123 complex and against the gC and combined gA and gB glycoprotein subcomponents of this complex were first tested for their ability to lyse wild-type virus-infected cells in the presence of complement. Wild-type virus-infected cells were lysed after treatment with each of the three antisera, demonstrating that the gC glycoprotein and the combined gA and gB glycoproteins can act as targets in the immune cytolysis reaction. Next, these antisera were used to select for mutants which were resistant to immune cytolysis. Cells infected with wild-type virus which had been mutagenized with 2-aminopurine and incubated at 39 degrees C were treated with one of the three types of antisera (anti-VP123 complex, anti-gC, or anti-gAgB) and lysed by the addition of complement. Cells which survived immune cytolysis were plated, and virus in the resulting plaques was isolated. Plaque isolates were tested for temperature sensitivity of growth and altered cytopathic effects in cell culture at 34 degrees C (the permissive temperature) and 39 degrees C. A total of 73 mutants was isolated in this manner. Selection with glycoprotein-specific antisera resulted in a 2- to 16-fold enrichment for mutants compared with "mock" -selected mutants using normal rabbit serum. Phenotypically, 24 mutants were temperature sensitive for growth, 27 were partially temperature sensitive, and 22 were not temperature sensitive but exhibited markedly altered cytopathic effects at both permissive and nonpermissive temperatures. Nine mutants of each phenotype (temperature sensitive, partially temperature sensitive, and non-temperature sensitive) were selected at random for confirmatory immune cytolysis tests with the antisera used in their selection. Cells infected with eight of the nine mutants were shown to be significantly more resistant to immune cytolysis at the nonpermissive temperature than were the mock-selected mutants or the wild-type virus from which they were derived.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6246268      PMCID: PMC288710     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Detection of a virus-specific antigen on the surface of herpes simplex virus-transformed cells.

Authors:  C L Reed; G H Cohen; F Rapp
Journal:  J Virol       Date:  1975-03       Impact factor: 5.103

2.  Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins.

Authors:  R W Honess; B Roizman
Journal:  J Virol       Date:  1974-07       Impact factor: 5.103

3.  Isolation and characterization of a large molecular-weight polypeptide of herpes simplex virus type 1.

Authors:  R J Courtney; M Benyesh-Melnick
Journal:  Virology       Date:  1974-12       Impact factor: 3.616

4.  Temperature-sensitive mutants of herpes simplex virus type 1: isolation, complementation and partial characterization.

Authors:  P A Schaffer; G M Aron; N Biswal; M Benyesh-Melnick
Journal:  Virology       Date:  1973-03       Impact factor: 3.616

5.  Proteins spcified by herpes simplex virus. II. Viral glycoprotins associated with cellular membranes.

Authors:  P G Spear; B Kellejmroian
Journal:  J Virol       Date:  1970-02       Impact factor: 5.103

6.  Proteins specified by herpes simplex virus. VI. Viral proteins in the plasma membrane.

Authors:  J W Heine; P G Spear; B Roizman
Journal:  J Virol       Date:  1972-03       Impact factor: 5.103

7.  Proteins specified by herpes simplex virus. V. Purification and structural proteins of the herpesvirion.

Authors:  P G Spear; B Roizman
Journal:  J Virol       Date:  1972-01       Impact factor: 5.103

8.  A temperature-sensitive mutant of herpes simplex virus defective in glycoprotein synthesis.

Authors:  P A Schaffer; R J Courtney; R M McCombs; M Benyesh-Melnick
Journal:  Virology       Date:  1971-11       Impact factor: 3.616

9.  Hydroxylapatite chromatography of protein-sodium dodecyl sulfate complexes. A new method for the separation of polypeptide subunits.

Authors:  B Moss; E N Rosenblum
Journal:  J Biol Chem       Date:  1972-08-25       Impact factor: 5.157

10.  Properties of hamster embryo fibroblasts transformed in vitro after exposure to ultraviolet-irradiated herpes simplex virus type 2.

Authors:  R Duff; F Rapp
Journal:  J Virol       Date:  1971-10       Impact factor: 5.103

View more
  12 in total

1.  Priscilla Schaffer (1941-2009): a stalwart herpesvirologist.

Authors:  Donald Coen
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

2.  Properties of the protein encoded by the UL32 open reading frame of herpes simplex virus 1.

Authors:  Y E Chang; A P Poon; B Roizman
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

Review 3.  Recent advances in cloning herpesviral genomes as infectious bacterial artificial chromosomes.

Authors:  Fuchun Zhou; Shou-Jiang Gao
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

4.  Kinetics of expression of herpes simplex virus type 1-specific glycoprotein species on the surfaces of infected murine, simian, and human cells: flow cytometric analysis.

Authors:  S R Jennings; P A Lippe; K J Pauza; P G Spear; L Pereira; S S Tevethia
Journal:  J Virol       Date:  1987-01       Impact factor: 5.103

5.  Characterization of herpesvirus sylvilagus glycoproteins released into the culture medium of infected cells: antisera to gp13 and gp32 neutralize viral infectivity in vitro and identify antigens on plasma membranes of infected cells.

Authors:  A K Patick; H C Hinze
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

Review 6.  Mutations that influence the secretory path in animal cells.

Authors:  A M Tartakoff
Journal:  Biochem J       Date:  1983-10-15       Impact factor: 3.857

7.  Genetic and phenotypic analysis of herpes simplex virus type 1 mutants conditionally resistant to immune cytolysis.

Authors:  B A Pancake; D P Aschman; P A Schaffer
Journal:  J Virol       Date:  1983-09       Impact factor: 5.103

8.  Mapping of a herpes simplex virus type 2-encoded function that affects the susceptibility of herpes simplex virus-infected target cells to lysis by herpes simplex virus-specific cytotoxic T lymphocytes.

Authors:  V C Carter; S R Jennings; P L Rice; S S Tevethia
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

9.  Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection.

Authors:  J T Rector; R N Lausch; J E Oakes
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

10.  Herpesvirus glycoprotein synthesis and insertion into plasma membranes.

Authors:  M L Peake; P Nystrom; L I Pizer
Journal:  J Virol       Date:  1982-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.